BRD7 and nasopharyngeal carcinoma: All of these findings suggest that the expression of BRD7 and miR-141 might serve as sensitive biomarkers in the early diagnosis of NPC; meanwhile, inhibitors specific for miR-141 could provide a promising strategy for NPC therapy.